Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers

Domvanalimab plus zimberelimab with chemotherapy demonstrated a positive overall response rate and 6-month progression free survival rate for patients with upper gastrointestinal cancers.

Related Keywords

United States ,American ,Yelenay Janjigian , ,Arcus Biosciences Inc ,Domvanalimab Gilead Sciences Inc ,Gilead Sciences Inc ,American Society ,Clinical Oncology Monthly Plenary ,Gastrointestinal Medical Oncology Service ,Memorial Sloan Kettering Cancer Center ,Arcus Biosciences ,